Valanbio Therapeutics Inc
Raleigh, NC · Founded 2015 · CIK 0001771623 · Biotech · Private
Small molecule LpxC inhibitors (lead compound LPC-233) targeting lipid A biosynthesis in Gram-negative bacteria
- Grants
- $3.2M
- 3 awards
- Sector median: 1
- Raised
- $121K
- 1 Form D · Sep 2019
- 85 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201920202021
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $121,000 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · IND-enabling studies of the potent LpxC inhibitor LPC-233 as a novel antibiotic against Gram-negative pathogens | $797,403 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · IND-enabling studies of the potent LpxC inhibitor LPC-233 as a novel antibiotic against Gram-negative pathogens | $1,591,745 | |
| Federal grant | Department of Health and Human Services · Phase II · IND-enabling studies of the potent LpxC inhibitor LPC-233 as a novel antibiotic against Gram-negative pathogens | $794,342 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1216 | OS Therapies Inc | — | $30M |
| 1217 | Universal Ibogaine Inc. | — | $135K |
| 1218 | Willowcroft Pharm Inc | — | $5.0M |
| 1219 | Valanbio Therapeutics Inc | — | $121K |
| 1220 | IMMUNOQ THERAPEUTICS INC. | — | — |
| 1221 | Aegle Therapeutics Corp | — | $6.7M |
| 1222 | Intelligent Therapeutics, Inc. | — | $100K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Clayton DuncanDirector · Executive Officer
- Sam HopkinsDirector
- Moise KhayrallahDirector · Executive Officer
- Eric TooneDirector
- Pei ZhouDirector · Executive Officer
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.